{'fraction_non_alphanumeric': 0.025136612021857924, 'fraction_numerical': 0.0, 'mean_word_length': 6.046153846153846, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacy Involvement With Positron-Emitting Radiopharmaceuticals

Positron emission tomography (PET) is an imaging process that relies on positron-emitting nuclides with very short physical half-lives (ranging from seconds to minutes). Exceptional resolution in PET imaging enables studies of the CNS (eg, highlighting deviant cell metabolism), and cardiovascular system (eg, identifying areas of reduced blood flow before coronary artery bypass surgery), among others. Increasing in popularity, PET radiopharmaceuticals pose a unique challenge to the nuclear pharmacist relative to product synthesis and quality control testing. Establishment of process validation programs with emphasis on quality, purity, and safety is all important. Various elements of process validation and quality control testing are discussed as they pertain to PET radiopharmaceuticals and the professional role of the nuclear pharmacist.